Nontuberculous Mycobacteria in China-incidence and Antimicrobial Resistance Spectrum From a Nationwide Survey

Liu, Chunfa; Song, Yimeng; He, Wencong; Liu, Dongxin; He, Ping; Bao, Jingjing; Wang, Xinyang; Liu, Yanming; Zhao, Yanlin

doi:10.21203/rs.3.rs-197161/v1

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As second-line drugs for MAC disease, the clinical efficacy of moxifloxacin and linezolid remains uncertain [40]. In our study, both had limited activity against MAC isolates, which is comparable with previous studies in Korea [41], Sweden [39], and China [42]. However, unlike the poor activity in vitro, a recent study has shown that fluoroquinolone-containing regimens could achieve similar clinical improvement with the standard regimen and could be an alternative for patients who cannot tolerate the standard regimen [43].…”

Section: Discussionsupporting

confidence: 85%

In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

et al. 2022

View full text Add to dashboard Cite

Background Recently, Mycobacterium avium complex (MAC) infections have been increasing, especially in immunocompromised and older adults. The rapid increase has triggered a global health concern due to limited therapeutic strategies and adverse effects caused by long-term medication. To provide more evidence for the treatment of MAC, we studied the in vitro inhibitory activities of 17 antimicrobial agents against clinical MAC isolates. Results A total of 111 clinical MAC isolates were enrolled in the study and they were identified as M. intracellulare, M. avium, M. marseillense, M. colombiense, M. yongonense, and two isolates could not be identified at the species level. MAC strains had relatively low (0–21.6%) resistance to clarithromycin, amikacin, bedaquiline, rifabutin, streptomycin, and clofazimine, and the resistant rates to isoniazid, rifampin, linezolid, doxycycline, and ethionamide were very high (72.1–100%). In addition, M. avium had a significantly higher resistance rate than that of M. intracellulare for ethambutol (92.3% vs 40.7%, P < 0.001), amikacin (15.4% vs 1.2%, P = 0.049), and cycloserine (69.2% vs 25.9%, P = 0.004). Conclusions Our results supported the current usage of macrolides, rifabutin, and aminoglycosides in the regimens for MAC infection, and also demonstrated the low resistance rate against new drugs, such as clofazimine, tedizolid, and bedaquiline, suggesting the possible implementation of these drugs in MAC treatment.

show abstract

Section: Discussionsupporting

confidence: 85%

In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The most prevalent NTM subspecies are MAC and MABc, both of which were the most common NTMs in patients with anti-IFN-γ Abs in previous studies [11,19], as well as the most common pathogenic NTMs in China [20][21]. Other opportunistic infections were rare in our study.…”

Section: Discussionsupporting

confidence: 42%

Characteristic clinical features and plasma cytokine profiles in patients infected with nontuberculous mycobacteria and Talaromyces marneffei due to anti–interferon-gamma autoantibodies

Lin¹,

Zhang²,

He³

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to explore the characteristic clinical and laboratory findings in patients infected with nontuberculous mycobacteria (NTM) and Talaromyces marneffei due to anti–interferon-gamma autoantibodies (anti–IFN-γ Abs). Methods A case-control study was conducted on 77 HIV-negative patients with NTM or T. marneffei infections. Anti–IFN-γ Abs were detected in these patients, and the expression levels of 45 cytokines in the plasma of patients with and without anti-IFN-γ Abs. Results Among the 77 patients enrolled, anti–IFN-γ Abs were detected in 32 (41.6%) patients. Patients with anti–IFN-γ Abs were more likely to exhibit fever, lymphadenopathy, and weight loss (all P < 0.001), and infections in the bones/joints and lymph nodes (P = 0.008, P = 0.006, respectively) were significantly more common. In addition, patients with anti–IFN-γ Abs showed higher levels of white blood cell counts (P < 0.001), neutrophil ratio (P = 0.035), platelet count (P < 0.001), erythrocyte sedimentation rate (P = 0.002), C-reactive protein (P = 0.009), and IgA (P = 0.004), and lower lymphocyte ratio (P = 0.007), hemoglobin (P = 0.047), CD4+ T lymphocyte ratio (P = 0.037), and serum albumin/globulin (P < 0.001). The autoantibody levels were found to be corelated with the IgG and serum globulin levels. Furthermore, the plasma levels of IL-8, IL-15, IL-10, IL-6, MCP-1, VEGF, TNF-α, MIP-3α, MIP-3β, and IL-1Ra significantly increased in patients with anti–IFN-γ Abs. Conclusion The characteristic clinical and laboratory findings will potentially help identify patients infected with NTM and T. marneffei due to anti–IFN-γ Abs.

show abstract

“…Prenatal exposure to DES is related to clear cell adenocarcinoma of the cervix and vagina. The expression of the EZH2 gene in the mammary gland is increased upon in-utero exposure to DES or bisphenol-A [68]. The over expression of EZH2 is associated with proliferation and progression of cervical cancer and poor prognosis [69].…”

Section: Cervical Cancermentioning

confidence: 99%

The Scenario of Recurrence of Cervical Cancer by Epigenetics

Gaikwad

2023

IJRASET

View full text Add to dashboard Cite

Epigenetic changes happen all the time during life, however, some differences are responsible for specific diseases. One such disease is cancer; nevertheless, a cancer recurrence can be exceedingly lethal and hasten the demise process. Epigenetic changes have the power to completely rule out all current modalities of treatment and have a rapid and substantial impact on the recurrence of cancer. Research indicates that recurrences may occur in up to 70% of individuals with stage III to IVB of cervical cancer. Even with extensive therapy, the 5-year overall survival (OS) rate for recurrent cervical cancer is less than 5%, and the disease is still extremely difficult to treat. This is particularly true for those who experience recurrence in a region that has previously undergone radiation treatment. Therefore, it is important to comprehend the role that epigenetic plays in cervical cancer recurrence since this will provide novel opportunities for treatment options. The purpose of this study was to evaluate the current developments in the field of epigenetic research on cervical cancer recurrence, including the role these alterations play in the evolution of the illness, their prognostic significance, and their application in targeted therapy.

show abstract

Nontuberculous Mycobacteria in China-incidence and Antimicrobial Resistance Spectrum From a Nationwide Survey

Cited by 3 publications

References 18 publications

In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

Characteristic clinical features and plasma cytokine profiles in patients infected with nontuberculous mycobacteria and Talaromyces marneffei due to anti–interferon-gamma autoantibodies

The Scenario of Recurrence of Cervical Cancer by Epigenetics

Contact Info

Product

Resources

About